ERNA Ernexa Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 748592 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY755.9%
TTM net income YoY-105.6%
TTM EPS YoY-1,100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin83.5%
Operating margin-2,693.1%
Net margin-7,652.7%
FCF margin-2,784.4%
EBITDA margin-2,648.8%
Returns
ROE-2,264.3%
ROA-163.7%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets67.7%
Debt / equity0.00x
Current ratio0.80x
Interest coverage2.09x
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-105.5%
Payout ratio—
Capex / revenue63.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | $1,000 |
| Cost of revenue | $0 | $0 | — | — | $0 | $0 | — | $0 |
| Gross profit | — | — | — | — | — | — | — | $1,000 |
| R&D expense | $1.87M | $2.79M | $1.92M | $676,000 | $1.03M | $1.14M | $1.31M | $1.16M |
| SG&A expense | $1.12M | $1.31M | $1.63M | $1.42M | $958,000 | $1.36M | $1.42M | $1.54M |
| Operating income | -$2.99M | -$4.10M | -$5.59M | -$2.09M | -$1.99M | -$2.50M | -$2.73M | -$2.70M |
| Interest expense | — | — | — | -$122,000 | $0 | -$778,000 | $6,000 | -$10.10M |
| Pretax income | -$2.94M | -$4.01M | -$5.55M | -$1.56M | -$1.23M | -$3.14M | -$8.19M | -$5.75M |
| Income tax | $0 | $0 | -$40,000 | -$62,000 | $6,000 | $3,000 | $8,000 | $11,000 |
| Net income | -$2.94M | -$4.01M | -$5.51M | -$1.50M | -$1.24M | -$3.14M | -$8.20M | -$5.76M |
| EBITDA | -$2.89M | -$4.00M | -$5.58M | -$2.08M | -$1.99M | -$2.00M | -$2.71M | -$2.68M |
| EPS (basic) | -1.89 | -3.40 | -6.95 | — | -3.77 | -15.19 | -57.76 | — |
| EPS (diluted) | -1.89 | -3.40 | -6.95 | — | -3.77 | -15.19 | -57.76 | — |
| Weighted avg. shares (diluted) | 1.56M | 1.18M | 792,000 | — | 329,000 | 207,000 | 142,000 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $5.58M | $5.03M | $9.18M | $1.88M | $3.05M | $4.32M | $1.92M | $1.73M |
| Current assets | $6.73M | $5.89M | $10.00M | $3.13M | $3.38M | $4.79M | $2.21M | $2.35M |
| PP&E, net | $73,000 | $82,000 | $88,000 | $94,000 | $92,000 | $50,000 | $67,000 | $85,000 |
| Goodwill | — | — | — | $2.04M | $2.04M | $2.04M | $2.04M | $2.04M |
| Total assets | $7.10M | $6.32M | $10.54M | $5.83M | $6.17M | $7.58M | $5.06M | $5.27M |
| Current liabilities | $2.61M | $2.93M | $3.46M | $3.11M | $2.14M | $2.65M | $10.44M | $2.94M |
| Total liabilities | $2.75M | $3.12M | $3.68M | $3.43M | $2.60M | $3.14M | $11.01M | $3.57M |
| Shareholders' equity | $4.35M | $3.20M | $6.86M | $2.40M | $3.57M | $4.44M | -$5.95M | $1.70M |
| Shares outstanding | 1.65M | 1.17M | 1.17M | 314,000 | 7.85M | 7.48M | 52.25M | 3.43M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.17M | -$4.15M | -$2.26M | -$1.15M | -$1.27M | -$2.53M | -$2.06M | -$3.54M |
| Capital expenditure | $0 | $3,000 | $2,000 | $15,000 | — | — | — | $0 |
| Free cash flow | -$3.17M | -$4.16M | -$2.27M | -$1.16M | — | — | — | -$3.54M |
| Investing cash flow | $0 | -$3,000 | -$2,000 | -$15,000 | — | — | — | $0 |
| Financing cash flow | $3.72M | $6,000 | $9.56M | $0 | $26,000 | $4.93M | $2.25M | $1.01M |
| Depreciation & amortization | $100,000 | $100,000 | $8,000 | $13,000 | $0 | $500,000 | $18,000 | $19,000 |
| Stock-based compensation | $377,000 | $320,000 | $309,000 | $333,000 | $293,000 | $368,000 | $502,000 | $410,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.